Patients are randomized to receive either cisplatin @ mg/m ( @ ) and etoposide @ mg/m ( @ ) intravenously on days @ to @ ( control arm ) or the same chemotherapy combined with bevacizumab @ mg/kg intravenously on day @ ( experimental arm ) .